• No results found

Rituximab Treatment in New and Refractory Thrombotic Thrombocytopenic Purpura (TTP) Patients: A Review

N/A
N/A
Protected

Academic year: 2020

Share "Rituximab Treatment in New and Refractory Thrombotic Thrombocytopenic Purpura (TTP) Patients: A Review"

Copied!
6
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Table 1: Characteristics of patients with New-onset TTP.
Table 2: Characteristics of patients with Refractory TTP.
Table 5: Number and sex of relapse and failure cases post-Rituximab therapy.

References

Related documents

As the donor site problems is concerned, the work of Wei [23] done on fifteen patients reconstructed with bilateral radial free forearm flap after surgical release of sub

Results: Thematic content analysis of the interviews resulted in 6 major themes, including (1) Familiarity with medication safety & adverse drug reaction concept (2) Current

BE: Bioequivalence; BW: Biowaiver; CD: Calendar days; CDDA: Cosmetics Devices and Drugs Authority; CDSCO: Central Drugs Standard Control Organization; CTD: Common technical

Deschauer M, Breunig F, Glocker FX, Vielhaber S, et al : Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2:

A small number of reports of rare, attenuated forms of CHS exist, with affected individuals exhibiting progressive neurodegenerative disease beginning in early adulthood with

Background: The objective of this systematic review was to determine the effectiveness and safety of propranolol compared to placebo or usual care for improving clinical

In 14 cases, it was extended throughout the splanchnic district, whilst in 6 patients it involved mainly the ileum and the colon (right colon 2 cases; left colon 3 cases; entire colon

A significant difference in the relative risk to be sero- logically MV positive for sheep with one or two copies of the CCR5 promoter wild type allele, compared to sheep without